The metabolic syndrome

Heart and Metabolism

Volumn , Issue 30, 2006, Pages

  Boehm, Bernhard O ^a   Schiekofer, Stephan ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Diabetes; Dyslipidemia; Hyperglycemia; Lifestyle modification; Metabolic syndrome; Pleiotropic effects

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; PHOSPHODIESTERASE I;

ARTICLE; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; DYSLIPIDEMIA; EATING HABIT; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; MEDICAL EXAMINATION; MEDICAL SOCIETY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PLEIOTROPY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; WORLD HEALTH ORGANIZATION;

EID: 33745774838     PISSN: 15660338     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
2. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med. 1998;15:539-553.
3. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization, 1999. Available from: http://whqlibdoc.who.int/hq/1999/ WHO_NCD_NCS_99.2.pdf. [Accessed 2003 Dec 12].
4. Alberti K, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus. The metabolic syndrome - a new worldwide definition. Lancet. 2005;366:1059-1062.
5. Haller H, Leonhardt W, Moser W, Hanefeld M. Relation of blood pressure to the body weight index and to metabolic parameters. Z Gesamte Inn Med. 1973;28S:211-213.
6. Meigs JB, D'Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes. 1997;46:1594-1600.
7. Reaven GM. Syndrome X. Blood Press. 1992;4S:13-16.
8. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991;34:416-422.
9. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
10. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
11. Meigs JB, Nathan DM, Wilson PW, Cupples LA, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: the Framingham Offspring Study. Ann Intern Med. 1998;128:524-533.
12. Gerstein HC. Is glucose a continuous risk factor for cardiovascular mortality? Diabetes Care. 1999;22:659-660.
13. Boehm BO, Claudi-Boehm S, Yildirim S, et al. Prevalence of the Metabolic Syndrome in Southwest Germany. Scand J Clin Lab Invest. 2005;240:122-128.
14. Lindström J, Louheranta A, Mannelin M. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003;26:3230-3236.
15. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New Engl J Med. 2001;344:1343-1350.
16. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med. 2002;346:393-403.
17. Kahn R, Ferranini E, Buse J, et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289-2304.
18. Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem. 2005;51:931-938.
19. Golden SH, Folsom AR, Coresh J, Sharrett AR, Szklo M, Brancati F. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. Diabetes. 2002;51:3069-3076.
20. Wilson PWF. Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view. Endocrinol Metab Clin N Am. 2004;33:467-481.
21. Wilson PWF, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999;159:1104-1109.
22. Meyre D, Bouatia-Naji N, Tounian A, et al. Variants of ENPP1 are associated with childhood and adult obesity and increase the risk of glucose intolerance and type 2 diabetes. Nat Genet. 2005;37:863-867.
23. Kahn B, Alquier T, Carling D, Hardie D. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1:15-25.
24. Shaw RJ, Lamina KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642-1646.
25. Pouliot MC, Després JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73:460-468.